PTC Therapeutics has agreed a cash and stock deal to acquire Agilis Biotherapeutics , in a bid to broaden its gene therapy portfolio. Agilis focuses on gene therapy programmes that target rare central nervous system disorders, and is currently seeking PTC approval for its two most advanced therapies. If the gene therapies for Friedreich’s ataxia and Angelman syndrome reach the market, Agilis shareholders would get another $150 million, plus 2 to 6 percent of the net sales of the drugs, according to the agreement. Through the terms of the acquisition, Agilis will pay $150 in cash and a further $595m m in shares, and if Agilis wins FDA approval, it could receive a further $595m .
PTC Therapeutics has agreed a cash and stock deal to acquire Agilis Biotherapeutics , in a bid to broaden its gene therapy portfolio. Agilis focuses on gene therapy programmes that target rare central nervous system disorders, and is currently seeking PTC approval for its two most advanced therapies. Through the terms of the acquisition, Agilis will pay $150 in cash and a further $595m m in shares, and if Agilis wins FDA approval, it could receive a further $595m .